Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Emerging Company Profile: Osivax is using its oligoDOM technology platform to developer a vaccine pipeline. The French biotech aims to establish proof-of-concept in influenza A then expand the pipeline to provide a universal flu vaccine.
Evotec upped its full-year guidance after a strong second quarter that saw an important strategic expansion into the biologics space through the acquisition of Just Biotherapeutics Inc.
The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.
Markets are re-assessing Amgen’s long-term value after a US judge upheld two patents relating to Amgen's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis and allowing investors to focus now on the pharma’s promising pipeline.
Merck KGaA said its second-quarter performance was boosted by its Life Science lab unit and milestone payments from drug development partners and promised analysts a pipeline update next month.
AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial data in metastatic castration-resistant prostate cancer, putting pressure on rival Clovis’s Rubraca.